BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26507833)

  • 21. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
    PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy.
    Segec A; Keller-Stanislawski B; Vermeer NS; Macchiarulo C; Straus SM; Hidalgo-Simon A; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):502-5. PubMed ID: 26250806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review.
    Henegar CE; Eudy AM; Kharat V; Hill DD; Bennett D; Haight B
    Lupus; 2016 May; 25(6):617-26. PubMed ID: 26743322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.
    Maas RP; Muller-Hansma AH; Esselink RA; Murk JL; Warnke C; Killestein J; Wattjes MP
    J Neurol; 2016 Oct; 263(10):2004-21. PubMed ID: 27401179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data.
    Holman RC; Janssen RS; Buehler JW; Zelasky MT; Hooper WC
    Neurology; 1991 Nov; 41(11):1733-6. PubMed ID: 1944901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
    Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
    J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus].
    Yukitake M
    Brain Nerve; 2019 May; 71(5):493-505. PubMed ID: 31088998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989.
    Gillespie SM; Chang Y; Lemp G; Arthur R; Buchbinder S; Steimle A; Baumgartner J; Rando T; Neal D; Rutherford G
    Ann Neurol; 1991 Oct; 30(4):597-604. PubMed ID: 1665053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
    García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
    Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2009 Dec; 60(12):3761-5. PubMed ID: 19950261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
    Parikh A; Stephens K; Major E; Fox I; Milch C; Sankoh S; Lev MH; Provenzale JM; Shick J; Patti M; McAuliffe M; Berger JR; Clifford DB
    Drug Saf; 2018 Aug; 41(8):807-816. PubMed ID: 29737503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.
    Bennett CL; Focosi D; Socal MP; Bian JC; Nabhan C; Hrushesky WJ; Bennett AC; Schoen MW; Berger JR; Armitage JO;
    Lancet Haematol; 2021 Aug; 8(8):e593-e604. PubMed ID: 34329579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
    Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
    Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
    Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
    Fleischmann RM
    Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.